Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7823224 | 0.81 | LMNA (0.46) | MAPK1TP53LMNAENPP2POLB | |
| SCHEMBL9977957 | 0.79 | MAPK1 (0.49) | TSHRMAPK1TP53LMNAPOLB | |
| SCHEMBL7740380 | 0.78 | MAPK1 (0.76) | TSHRMAPK1TP53LMNAPOLB | |
| SCHEMBL27939149 | 0.78 | AKT1 (0.42) | TSHRMAPK1TP53LMNAENPP2 | |
| SCHEMBL7831695 | 0.77 | ALDH1A1 (0.47) | TSHRLMNAPOLBMAPT | |
| SCHEMBL9977976 | 0.77 | PDE4B (0.45) | TSHRMAPK1TP53ENPP2POLB | |
| SCHEMBL9978098 | 0.76 | MAPK1 (0.37) | TSHRMAPK1TP53LMNA | |
| SCHEMBL18022583 | 0.76 | TBXA2R (0.42) | TSHRMAPK1LMNAMAPT | |
| SCHEMBL9977979 | 0.76 | TP53 (0.45) | TP53LMNAENPP2THRBMAPT | |
| SCHEMBL7740507 | 0.74 | MAPK1 (0.68) | TSHRMAPK1TP53LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | disclosed |
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | disclosed |
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-18 | — | — | US | disclosed |
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9321767-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-26 | — | — | US | disclosed |
| US-9321767-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-26 | — | — | US | disclosed |
| EP-2651933-B1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-16 | — | — | EP | disclosed |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-12 | — | — | US | disclosed |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-12 | — | — | US | disclosed |
| US-8927720-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN R&D IRELAND (IE) | 2015-01-06 | — | — | US | disclosed |
| US-8927720-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN R&D IRELAND (IE) | 2015-01-06 | — | — | US | disclosed |
| CN-103347881-A | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN R & D IRELAND | 2013-10-09 | — | — | CN | disclosed |
| US-20130261151-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R & D IRELAND (IE) | 2013-10-03 | — | — | US | disclosed |
| WO-2012080449-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | AZI2, ZC3HAV1, ZC3HAV1L | TSHR 4377/4885MAPK1 2430/4885TP53 2157/4885 |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, AZI2, ZC3HAV1L | TSHR 4359/4885MAPK1 2680/4885TP53 1918/4885 |
| US-20130261151-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, AZI2, ZC3HAV1L | TSHR 4359/4885MAPK1 2680/4885TP53 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.